Nicole M. Lioufas

Nicole M. Lioufas

Auto-generated profile, based on publicly available information

Nicole M. Lioufas

Department of Nephrology, The Royal Melbourne Hospital Parkville Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 February 2019 in International Journal of Hypertension
Verified
Journal Article
Open access
PDF file
NLNicole Lioufas
Nicole Lioufas
CHCarmel M. Hawley
Carmel M. Hawley
JCJames Donald Cameron
James Donald Cameron
NTNigel D. Toussaint
Nigel D. Toussaint
Chronic kidney disease (CKD) is associated with excess cardiovascular mortality, resulting from both traditional and nontraditional, CKD-specific, cardiovascular risk factors. Nontraditional risk factors include the entity Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) which is characterised by disorders of bone and mineral metabolism, including biochemical abnormalities of hyperphosphatemia and hyperparathyroidism, renal osteodystrophy, and vascular calcification. Increased arterial stiffness in the CKD population can be attributed amongst other influences to progression of vascular calcification, with significant resultant contribution to the cardiovascular disease burden. Pulse wave velocity (PWV) measured over the carotid-femoral arterial segments is the noninvasive gold-standard technique for measurement of aortic stiffness and has been suggested as a surrogate cardiovascular end-point. A PWV value of 10 m/s or greater has been recommended as a suitable cut-off for an increased risk of cardiovascular mortality. CKD is a risk factor for an excessive rate of increase in aortic stiffness, reflected by increases in PWV, and increased aortic PWV in CKD shows faster progression than for individuals with normal kidney function. Patients with varying stages of CKD, as well as those on dialysis or with a kidney transplant, have different biological milieu which influence aortic stiffness and associated changes in PWV. This review discusses the pathophysiology of arterial stiffness with CKD and outlines the literature on PWV across the spectrum of CKD, highlighting that determination of arterial stiffness using aortic PWV can be a useful diagnostic and prognostic tool for assessing cardiovascular disease in the CKD population.

5 February 2020 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
NLNicole M. Lioufas
Nicole M. Lioufas
EPEugenia Pedagogos
Eugenia Pedagogos
CHCarmel M. Hawley
Carmel M. Hawley
EPElaine M. Pascoe
Elaine M. Pascoe
GEGrahame Elder
Grahame Elder
OIon behalf of the IMPROVE-CKD Investigators
on behalf of the IMPROVE-CKD Investigators
Chronic kidney disease (CKD) is associated with excess cardiovascular morbidity and mortality compared to the general population. Hyperphosphataemia, associated with vascular calcification and arterial stiffness, may play a key role in the pathogenesis of cardiovascular disease (CVD) associated with CKD, although phosphate reduction strategies have not consistently proven to beneficially affect clinically relevant outcomes. The IMpact of Phosphate Reduction On Vascular End-points in CKD (IMPROVE-CKD) study is an international, multi-centre, randomized, placebo-controlled trial investigating the effect of the phosphate binder lanthanum carbonate on intermediate cardiovascular markers in patients with stage 3b–4 CKD. The primary end-point is change in carotid-femoral pulse wave velocity (PWV, SphygmoCor) after 96 weeks. Secondary outcomes include change in abdominal aortic calcification (AAC, computed tomography), serum phosphate and fibroblast growth factor 23 (FGF-23). In total, 278 participants were recruited and randomized, mean age 63 ± 13 years, 69% male, 45% diabetes, 32% CVD, 33% stage 3b CKD and 67% stage 4 CKD. Mean estimated glomerular filtration rate and serum phosphate were 26.6 ± 8.3 mL/min/1.72 m2 and 1.25 ± 0.20 mmol/L, respectively. Median (interquartile range) intact and c-terminal FGF-23 levels were 133.0 (89.1–202) pg/mL and 221.1 (154.3–334.1) RU/mL, respectively. Mean PWV was 10.8 ± 3.6 m/s and 81% had AAC (median Agatston score 1,535 [63–5,744] Hounsfield units). PWV ≥10 m/s was associated with older age, diabetes, CVD, presence of AAC, higher systolic blood pressure (BP), larger waist circumference and higher alkaline phosphatase. AAC was associated with older age, male sex, diabetes, CVD, higher diastolic BP, dyslipidaemia (and use of statins), smoking, larger waist circumference and increased PWV. In conclusion, IMPROVE-CKD participants had high baseline risk for cardiovascular events, as suggested by high baseline PWV and AAC values.

28 May 2021 in Nephrology
Verified
Journal Article
Closed access
PDF file
MTMark K. Tiong
Mark K. Tiong
SUShahid Ullah
Shahid Ullah
SMStephen P. McDonald
Stephen P. McDonald
STSven‐Jean Tan
Sven‐Jean Tan
NLNicole M. Lioufas
Nicole M. Lioufas
NTNigel D. Toussaint
Nigel D. Toussaint

31 December 2016 in Journal of Clinical Nephrology and Renal Care
Verified
Journal Article
Open access
NLNicole Lioufas
Nicole Lioufas
Pre-eclampsia is the most common medical complication of pregnancy affecting 3-5% of pregnancies worldwide. Traditional teaching has generally maintained that the natural history of Pre-eclampsia is one of resolution of renal pathology and other clinical features- some days to weeks after delivery of the placenta. Renal injury is mediated by both endothelial and podocyte injury in pre-eclampsia. In some women however, the renal injury does not resolve and proteinuria persists following pregnancy. The development of further glomerular lesions, notably focal segmental glomerulosclerosis (FSGS) following pre-eclampsia, has previously been described, and is an association that is increasingly recognized.